Phenylephrine
| Phenylephrine | |
|---|---|
| Salts [] | |
|---|---|
| Phenylephrine bitartrate | |
| Phenylephrine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 167.20 g/mol [1] |
| Melting point | 140-145 °C [1] |
| Solubility | Freely soluble in water [1] |
| Predicted LogP | -0.3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C9H13NO2 |
| IUPAC name | 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol |
| SMILES | CNC[C@@H](C1=CC(=CC=C1)O)O |
| InChI | InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1 |
| InChIKey | SONNWYBIRXJNDC-VIFPVBQESA-N |
| CAS number | 59-42-7 |
| UNII | 1WS297W6MV |
| PubChem CID | 6041 |
| Pharmacokinetics[] | |
|---|---|
| Onset | IV: Very rapid, Oral: 15–20 min, Intranasal: <2 min, Eye drop: <30 min |
| Elimination half-life | 2–3 hours |
| Duration of action | IV: 20 min–5 h, Oral: 2–4 h, Intranasal: 0.5–4 h, Eye drop: 3–7 h |
| Metabolism | Liver and intestines (via oxidative deamination by MAO-A and MAO-B; sulfation; glucuronidation) |
| Excretion | Urine: 86% (3–16% unchanged) |
| Routes of administration | Oral, intranasal, ophthalmic, intravenous, intramuscular, rectal |
Phenylephrine (also known as Metasynephrine, m-Oxedrine, Mezaton, m-Sympatol, Metasympatol, Mesatone, Visadron, m-Sympathol, m-Synephrine or Metaoxedrine) is a sympathomimetic substance of the phenylethanolamine class.
Chemistry
Salts []
Phenylephrine is typically found in the form of its bitartrate and hydrochloride salts.
Stereochemistry []
Phenylephrine is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Phenylephrine matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- cardiac therapy (C01)
- cardiac stimulants excl. cardiac glycosides (C01C)
- adrenergic and dopaminergic agents (C01CA)
- phenylephrine (C01CA06)
- vasoprotectives (C05)
- agents for treatment of hemorrhoids and anal fissures for topical use (C05A)
- other agents for treatment of hemorrhoids and anal fissures for topical use (C05AX)
- phenylephrine (C05AX06)
- respiratory system (R)
- nasal preparations (R01)
- decongestants and other nasal preparations for topical use (R01A)
- sympathomimetics, plain (R01AA)
- phenylephrine (R01AA04)
- sympathomimetics, combinations excl. corticosteroids (R01AB)
- phenylephrine (R01AB01)
- nasal decongestants for systemic use (R01B)
- sympathomimetics (R01BA)
- phenylephrine (R01BA03)
- sensory organs (S)
- ophthalmologicals (S01)
- mydriatics and cycloplegics (S01F)
- sympathomimetics excl. antiglaucoma preparations (S01FB)
- (S01FB01)
- phenylephrine (S01FB01)
- decongestants and antiallergics (S01G)
- sympathomimetics used as decongestants (S01GA)
- phenylephrine (S01GA05)
MeSH Classification
- cardiotonic agents (M0003471)
- mydriatics (M0014317)
- sympathomimetics (M0020947)
- vasoconstrictor agents (M0022551)
- nasal decongestants (M0022552)
- adrenergic alpha-1 receptor agonists (M0543920)
Mechanism of action []
Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction and mydriasis depending on the route and location of administration. Systemic exposure to phenylephrine also leads to agonism of alpha-1 adrenergic receptors, raising systolic and diastolic pressure as well as peripheral vascular resistance. Increased blood pressure stimulates the vagus nerve, causing reflex bradycardia. [1]
Interactions []
Medical side effects []
68 side effects listed on drug labels in SIDER 4.1 (phenylephrine).
- Arrhythmia
- Atrioventricular block
- Mental disorder
- Neck pain
- Chest pain
- Corneal oedema
- Arteriospasm coronary
- Dyspnoea
- Extravasation
- Vitreous floaters
- Gastrointestinal disorder
- Headache
- Cardiac disorder
- Hyperaemia
- Hypersensitivity
- Hypertension
- Hypertensive crisis
- Orthostatic hypotension
- Immune system disorder
- Ischaemia
- Keratitis
- Mediastinal disorder
- Miosis
- Myocardial infarction
- Acute coronary syndrome
- Nausea
- Nervous system disorder
- Nervousness
- Tension
- Pallor
- Blanching of skin
- Blanching
- Palpitations
- Paraesthesia
- Piloerection
- Pruritus
- Pulmonary oedema
- Rales
- Subarachnoid haemorrhage
- Dizziness
- Shock
- Syncope
- Loss of consciousness
- Tachycardia
- Tremor
- Trembling
- Underweight
- Angiopathy
- Vomiting
- Ventricular arrhythmia
- Agitation
- Excitability
- Photophobia
- Ventricular extrasystoles
- Myocardial ischaemia
- Skin necrosis
- Skin exfoliation
- Eye pain
- Skin disorder
- Bradycardia
- Abdominal pain upper
- Extrasystoles
- Vision blurred
- Lacrimation increased
- Blood pressure increased
- Pain
- Hyperhidrosis
- Sensitisation
Indications
- Cardiovascular disorder
- Cycloplegia
- Hypersensitivity
- Hypertensive
- Mydriasis
- Open angle glaucoma
- Paroxysmal supraventricular tachycardia
- Posterior synechiae of iris
- Shock
- Uveitis
Subjective effects []
Experience reports
Legal status []
- Australia: Phenylephrine is a Schedule 2.
- New Zealand: Phenylephrine is a OTC.
- United Kingdom: Phenylephrine is a GSL.
- United States: Phenylephrine is a OTC / Prescription only.
See also []
External links []
- Phenylephrine (Wikipedia)
- Phenylephrine (PubChem)
- Phenylephrine (Wikidata)
- Phenylephrine (DrugBank)
- Phenylephrine (ChEMBL)
- Phenylephrine (ChEBI)
- Phenylephrine (Common Chemistry)
- Phenylephrine (HMDB)
- Phenylephrine (KEGG)
- Phenylephrine (EPA DSSTox)
- Phenylephrine (Effect Index)
- Phenylephrine (UNII)
- Phenylephrine (SIDER)
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 6041, Phenylephrine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/6041
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Phenylephrine. UNII: 1WS297W6MV. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1WS297W6MV
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 09:12:32 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 09:12:28 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 09:12:28 |
| gsrs | ok | 2026-11-20 09:12:30 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0002182) | 2026-11-20 09:12:28 |
| kegg | ok | 2026-11-20 09:12:30 |
| pubchem | ok | 2026-11-20 09:12:28 |
| ok | 2026-11-20 09:12:28 | |
| sider | ok | 2026-11-20 09:12:28 |
| structure | ok | 2026-11-20 09:12:28 |
| wikipedia | ok | 2026-11-20 09:12:28 |